Quince Therapeutics regains compliance with Nasdaq listing requirements
Quince Therapeutics announced it has regained compliance with Nasdaq's listing requirements after reporting stockholders' equity of $15,672,000 in its latest quarterly report. This resolves a previous notification regarding the company's failure to maintain a minimum market value of listed securities. In other news, the company recently acquired Orphai Therapeutics, appointed a new board member, and enacted a 1-for-10 reverse stock split.
APR 2·Stock Titan▼
Quince Therapeutics (QNCX) delays 2025 10-K after failed Phase 3; seeks 15-day extension
Quince Therapeutics (QNCX) announced a delay in filing its 2025 Annual Report on Form 10-K, citing the need for additional time to complete accounting procedures due to recent headcount reductions and the negative results from a Phase 3 clinical trial. The company expects to file the report within the 15-calendar-day extension permitted by Rule 12b-25. This delay is attributed to the complexities arising from the failed Phase 3 study, which did not meet its primary endpoint, leading to strategic actions including staff reductions.
MAR 31·GuruFocus▼
Quince Therapeutics (QNCX) Resolves Debt with European Investment Bank
Quince Therapeutics (QNCX) has successfully resolved its debt with the European Investment Bank by paying $5.5 million, settling outstanding obligations of $16.4 million. The biopharmaceutical company, focused on rare diseases, faces significant financial challenges as indicated by a Piotroski F-Score of 3 and ongoing losses, despite moderate institutional interest and cautious analyst recommendations. Its future market position depends on addressing operational and financial hurdles beyond this debt restructuring.
